根据最终合并协议,Viewpoint的每一股已发行和流通股份将转换为获得Isoray 3.3212股的权利。Viewpoint股东将拥有Isoray完全稀释的流通股49%的股份。
$华海药业(SH600521)$ $华东医药(SZ000963...查看全文
$Isoray(ISR)$ 8-K Current report, items 1.01, 5.02, 5.07, 7.01, and 9.01 Accession Number: 0001437749-22-029080 Act: 34 Size: 598 KB 网页链接
$Isoray(ISR)$ DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material Accession Number: 0001437749-22-029081 Act: 34 Size: 43 KB 网页链接
$Isoray(ISR)$ DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material Accession Number: 0001437749-22-028546 Act: 34 Size: 1 MB 网页链接
$Isoray(ISR)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001437749-22-028455 Size: 5 KB 网页链接
$Isoray(ISR)$ 8-K Current report, items 1.01, 8.01, and 9.01 Accession Number: 0001437749-22-028154 Act: 34 Size: 260 KB 网页链接
$Isoray(ISR)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001437749-22-027681 Size: 4 KB 网页链接
$Isoray(ISR)$ 424B5 Prospectus [Rule 424(b)(5)] Accession Number: 0001437749-22-027559 Act: 33 Size: 569 KB 网页链接
$Isoray(ISR)$ 10-Q Quarterly report [Sections 13 or 15(d)] Accession Number: 0001437749-22-027304 Act: 34 Size: 3 MB 网页链接
$Isoray(ISR)$ 8-K Current report, items 2.02, 8.01, and 9.01 Accession Number: 0001437749-22-026895 Act: 34 Size: 288 KB 网页链接
$Isoray(ISR)$ DEFM14A Definitive proxy statement relating to merger or acquisition Accession Number: 0001437749-22-026217 Act: 34 Size: 8 MB 网页链接